Evidence map›Paper›PMID 17114012›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2006

Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.

Siong-Seng Liau, Stanley W Ashley, Edward E Whang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. HMGA1 in cancer: Cancer classification by location.Journal of cellular and molecular medicine · 2019
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  10. CXCR7 expression in nasopharyngeal carcinoma tissues correlates with disease severity.International journal of clinical and experimental medicine · 2015
    Article
  11. [Advances of lentiviral vectors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014
    Review
  12. Review
  13. Article
  14. Current knowledge on pancreatic cancer.Frontiers in oncology · 2012
    Article
  15. Article
  16. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2010
    Article
  17. High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland · 2009
    Review
  18. Pancreatic cancer: molecular pathogenesis and new therapeutic targets.Nature reviews. Gastroenterology & hepatology · 2009
    Review
  19. Article
  20. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Siong-Seng LiauDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Stanley W Ashley
Edward E Whang
Harvard University · USBrigham and Women's Hospital · US

Funding

Biomarkers and Therapeutic Targets in Pancreatic CancerR01CA114103 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI WHANG, EDWARD E · 2005 to 2009
$1.5M
NCI NIH HHS 1-R01-CA114103
6 · The paper itself

Abstract

The high mobility group A1 (HMGA1) proteins are overexpressed in pancreatic cancers. They are architectural nuclear proteins, which regulate expression of multiple genes implicated in the malignant phenotype. In this study, we hypothesized that HMG A1 silencing will promote chemosensitivity in pancreatic adenocarcinoma. We studied highly malignant pancreatic adenocarcinoma cell lines (MiaPaCa2 and PANC1). Lentiviral short-hairpin RNA (shHMGA1) expression vectors targeting HMGA1 were used for generation of lentiviral particles. Stable transfectants were developed after lentiviral transduction. Nuclear expression of HMGA1 was assayed using Western blot analysis. Chemosensitivity to gemcitabine was determined by IC50 analysis. Caspase activity was quantitated using fluorometric caspase profiling. Apoptosis was assessed by flow cytometric analysis. Lentivirus-mediated RNA interference resulted in 90% silencing of HMGA1 expression in each of MiaPaCa2 and PANC1 cell lines. HMGA1 silencing enhanced chemosensitivity to gemcitabine with an approximately 50% reduction in IC50 in each cell line. Lentivirus-mediated HMGA1 silencing promoted the activation of caspases 3, 2, 9, and 8, on exposure to gemcitabine. HMGA1 silencing resulted in reduction in Akt kinase activity. Lentivirus-mediated RNA interference of HMGA1 promoted chemosensitivity to gemcitabine in pancreatic adenocarcinoma. HMGA1 may represent a novel therapeutic target in pancreatic cancer.

Indexed as

Antimetabolites, AntineoplasticApoptosisCarcinoma, Pancreatic DuctalCaspasesCell Line, TumorDeoxycytidineDrug Resistance, NeoplasmGemcitabineHMGA ProteinsHumansLentivirusPancreatic NeoplasmsProto-Oncogene Proteins c-aktRNA InterferenceAntimetabolites, AntineoplasticCaspasesDeoxycytidineGemcitabineHMGA ProteinsProto-Oncogene Proteins c-akt

Identifiers

PMID17114012
OpenAlexW2053318315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.